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Introduction
The First International Conference on Inhibitors 
in Haemophilia A was held on 4-5 March, 2016. 
The major theme was the development of factor 
VIII (FVIII) inhibitors, which occurs in 30-35% of 
previously untreated children infused with the available 
commercial products. This meeting was the occasion 
for a comprehensive discussion on the data that are 
emerging from recent studies and international registries. 
Mechanisms of inhibitor development 
Alloantibodies and autoantibodies
Sebastien Lacroix-Desmazes opened this conference 
with a presentation concerning the mechanism of 
inhibitor development. The first evidence of the presence 
of natural anti-FVIII antibodies came in 1992, with 
the demonstration that heat-treated plasma of 17% of 
unselected healthy blood donors with otherwise normal 
levels of circulating FVIII contained antibodies that 
were able to inhibit the procoagulant activity of FVIII 
in a functional coagulation assay. It was discovered that 
such antibodies are natural IgG autoantibodies and/or 
antibodies directed against epitopes, associated with a 
so far unidentified allotypic polymorphism of the human 
FVIII molecule. These findings indicate that the presence 
of anti-FVIII antibodies is a universal phenomenon, more 
common than previously thought and that anti-idiotypic 
antibodies capable of inhibiting the binding of anti-FVIII 
antibodies to FVIII are produced spontaneously. 
Under physiological conditions, there is a steady-
state interaction of FVIII with the immune system; 
at the humoral level, tolerance to FVIII relies on an 
equilibrium between the recognition of FVIII by 
naturally occurring, potentially inhibitory anti-FVIII 
antibodies and their control by neutralising anti-idiotypic 
antibodies. Neutralising anti-idiotypic antibodies may 
also regulate the B-cell clones that secrete the FVIII-
specific autoantibodies. At the T-cell level, natural 
FVIII-reactive T cells may be down-regulated by natural 
regulatory T cells (i.e., CD4+ CD25+ FoxP3+ T cells) 
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and/or by induced transforming growth factor (TGF-β)-
secreting regulatory T cells.
Neutralising antibodies against FVIII remain 
the major complication of therapy for patients 
with haemophilia A. In order to understand the 
evolution of these antibodies better, it was important 
to generate comprehensive datasets, which included 
both neutralising and non-neutralising antibodies, 
their isotypes and IgG subclasses. Literature data 
revealed significant differences for IgG subclasses of 
FVIII-binding antibodies among the different study 
cohorts. IgG4 and IgG1 were the most abundant IgG 
subclasses in patients with FVIII inhibitors. Strikingly, 
IgG4 was completely absent in patients with no FVIII 
inhibitors and in healthy subjects. These findings 
pointed towards a distinct immune regulatory pathway 
responsible for the development of FVIII-specific 
IgG4 associated with FVIII inhibitors. Prompted by 
these findings, the distinguishing properties among the 
different populations of FVIII-specific antibodies were 
investigated. It was hypothesised that the affinity of 
antibodies would discriminate between the neutralising 
and non-neutralising antibodies found in different 
study cohorts. To test this idea, competition-based 
enzyme-linked immunosorbent assays were designed to 
assess the apparent affinities for each isotype and IgG 
subclass of FVIII-specific antibodies without the need 
for antibody purification. FVIII-specific antibodies, 
found in patients with FVIII inhibitors, had an up to 
100-fold higher apparent affinity than antibodies found 
in patients without inhibitors and in healthy individuals. 
FVIII-specific IgG4 found in patients with congenital 
haemophilia A and FVIII inhibitors expressed the 
highest affinity of all IgG subclasses. Considering 
these findings, it was suggested that these antibodies 
may serve as potential biomarkers for evolving FVIII 
inhibitor responses in clinical research.
The role of B and T cells and novel therapeutic 
approaches
David W. Scott presented data on the mechanisms 
of induction of tolerance to FVIII, focussing on the 
generation of engineered FVIII-specific human T 
regulatory cells. The primary immune response is 
initiated by the internalisation of therapeutically 
administered FVIII by professional antigen-presenting 
cells (e.g. dendritic cells) and its subsequent presentation 
to naïve FVIII-specific CD4+ T cells. Activated CD4+ T 
cells in turn activate FVIII-specific naïve B cells, which 
proliferate and differentiate into either plasmocytes 
(antibody-secreting cells) or FVIII-specific memory B 
cells. During the secondary immune response, FVIII-
specific memory B cells generated during the primary 
immune response act as antigen-presenting cells and 
activate FVIII-specific CD4+ T cells. With the help of 
CD4+ T cells, FVIII-specific memory B cells further 
differentiate into antibody-secreting cells. In parallel, 
uptake of FVIII by professional antigen-presenting 
cells results in activation of T cells that, in turn, activate 
new FVIII-specific B cells and thus generate additional 
antibody-secreting cells and memory B cells. Hence, 
novel therapeutic strategies directed at the elimination 
of FVIII inhibitors in haemophilia A patients who have 
developed alloimmunisation to FVIII may be achieved 
by FVIII-specific targeting of immune effectors, for 
instance by manipulation of the idiotypic network. 
Alternatively, immune reactions to therapeutic FVIII 
may be avoided in previously untreated patients 
(PUPs) by using structurally modified FVIII, of which 
the dominant T- and B-cell epitopes and/or structures 
of FVIII that mediate its internalisation by antigen-
presenting cells have been altered. Simultaneously, 
assessment of the inflammatory state of the patient may 
help clinicians to reduce the risk of alloimmunisation.
It was suggested that recombinant factor VIII (rFVIII) 
products are more immunogenic than plasma-derived 
products (pdFVII). There is biological plausibility 
that pdFVIII may be less immunogenic than rFVIII. 
Being extracted from human plasma, these products 
are more native than FVIII produced by recombinant 
DNA technology from mammalian cell lines, which 
causes post-translational modifications in the FVIII 
molecule. pdFVIII products may be less immunogenic 
because of their high content of the chaperone protein 
von Willebrand factor (VWF), which may reduce 
immunogenicity masking FVIII epitopes and protecting 
from endocytosis which is mediated by antigen-presenting 
cells. Moreover, pdFVIII contains human proteins that 
may have immunomodulatory properties. 
Inhibitor data collection systems 
United Kingdom, French, Canadian National 
Registries and European data on previously 
untreated patients and previously treated patients
A cohort study involving 574 consecutive, previously 
untreated children with severe haemophilia A, who were 
born between 2000 and 2010, was designed to evaluate 
whether the type of FVIII product and switching among 
products were associated with inhibitor development 
(RODIN study). In this cohort, recombinant and 
plasma-derived FVIII products conferred similar risks 
of inhibitor development, and the content of VWF 
in the products and switching among products were 
not associated with the risk of inhibitor development. 
Second-generation full-length recombinant products 
were associated with an increased risk, when compared 
to third-generation products. These results were in 
agreement with the findings of a similarly designed 
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study, entitled Concerted Action on Neutralizing 
Antibodies in Severe Haemophilia A (CANAL) study, 
in which the risk of inhibitor development was not 
clearly lower with plasma-derived products than with 
recombinant products. 
Three additional retrospective observational 
studies from France (FranceCoag), the United 
Kingdom (UKHCDO) and Canada, presented by 
Jenny Goudemand, substantially confirmed that rFVIII 
products were associated with an approximately 60% 
higher inhibitor rate in PUPs. Both the RODIN and 
FranceCoag cohort studies reported that the cumulative 
incidence rates of inhibitor development by 75 exposure 
days (ED) were 32.4% and 40.2% for all inhibitors, and 
22.4% and 23.9% for high-titre inhibitors in the RODIN 
study and in the FranceCoag, respectively.
In addition, Marijke van den Berg presented the 
PedNet Haemophilia Registry, which is a collaborative 
effort of the European PEDiatric NETwork for 
haemophilia management. This registry was set up in 
2004 by PedNet investigators to promote and facilitate 
research and healthcare development in children with 
haemophilia. At the moment, 31 haemophilia treatment 
centres from 16 countries are collaborating. The aim 
of the PedNet registry is to include complete cohorts 
of all newly diagnosed patients born from January 
2000 onwards with congenital haemophilia A or B 
(FVIII/IX≤0.25 IU/dL) who are treated in one of the 
participating centres. The data collected include many 
clinical, laboratory and genetic parameters, which 
makes the registry suitable for a large variety of research 
questions. Currently 1,531 children are included in the 
PedNet registry, of whom more than 1,000 have severe 
haemophilia A or B. The first cohort of patients was born 
between 2000 and 2010. Inclusion of children born from 
2010 onwards (second cohort) is ongoing. Data collected 
in the PedNet registry (for cohorts I and II) showed 
that inhibitor development was influenced by many 
genetic and non-genetic risk factors, and the incidence 
of inhibitor development following the use of plasma-
derived or recombinant products was similar. Moreover 
the analysis of the data originating from a European 
Surveillance Registry (EUHASS), presented by Michael 
Makris, showed that there were no class or brand-related 
differences among the various rFVIII products employed 
in 68 European centres in PUPs and previously treated 
patients (PTPs). 
Inhibitor development in previously untreated 
patients
The hypothesis of less inhibitor formation with 
pdFVIII was supported clinically by a number of 
observational studies, which found a lower cumulative 
incidence of inhibitors in PUPs with severe haemophilia A 
treated exclusively with pdFVIII: 14.5% vs 31% for those 
treated with rFVIII. Although these different inhibitor 
rates apparently confirmed a higher immunogenicity 
for rFVIII, the effect of the FVIII source was found to 
be mainly due to confounders. Hence, meta-analytic 
findings stemming from observational studies were 
inconclusive and the performance of randomised trials 
was necessary. 
Results of the SIPPET
On this background, Frits R. Rosendaal shared the 
results of the Study on Inhibitors in Plasma-Product 
Exposed Toddlers (SIPPET). The SIPPET was an 
investigator-driven, worldwide, prospective, open-label 
clinical trial examining 300 PUPs or minimally treated 
patients with severe haemophilia A and was designed to 
establish whether or not there was a different incidence 
of inhibitors between patients randomised to the class 
of pdFVIII products containing VWF or that of rFVIII 
not containing VWF. By univariate Cox regression 
analysis rFVIII was associated with an 87% higher 
incidence of inhibitors than pdFVIII. For high-titre 
inhibitors, the rate increased 70%. The associations 
did not change materially after adjustment for 
putative confounders: in adjusted models the rate 
remained elevated by 70-90% for rFVIII vs pdFVIII. 
When the analysis was restricted to sites that had not 
randomised patients to a second-generation, full-length 
rFVIII or pdFVIII, the risk associated with other rFVIII 
concentrates vs pdFVIII was still two-fold higher. In 
conclusion, in this study the class of rFVIII products was 
associated with a 1.87-fold higher incidence of inhibitors 
than that of the pdFVIII class. This difference remained 
even when second-generation, full-length rFVIII 
concentrates were excluded from the analyses. The 
results of this randomised study may have implications 
for the choice of product for the management of PUPs: 
to treat all PUPs with pdFVIII, to treat first with pdFVIII 
and then switch to rFVIII, or differentiate low-risk 
rFVIII and high-risk pdFVIII.
Inhibitor development in previously treated 
patients
Although common in PUPs, inhibitor development 
is rare in multiply exposed, well-tolerated patients. In 
this regard, Michael Makris reported that the observed 
rate of inhibitors in PTPs is approximately 2 per 1,000 
patient/years, which makes it difficult to study them 
and compare rates among different products. He also 
described a non-evidence-based reluctance to change 
concentrate because of a greater perceived risk of 
inhibitor development after product switching. Two 
reports about outbreaks of inhibitor formation after 
product switching in the 1990s, two reports from 
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Canada, one from the United Kingdom, two from 
Ireland and some others were discussed: the single 
robust conclusion was that there was no clear signal of 
increased inhibitor development when switching to or 
from the currently available factor concentrates. 
A recent systematic review considered the studies 
reporting on PTPs which were included in the Wight 
and Paisley meta-analysis as well as studies published 
after 2003, which were identified by a systematic 
search of MEDLINE, EMBASE, and The Cochrane 
Library. Studies that investigated the development of 
inhibitors in PTPs with haemophilia A who were treated 
with any type of FVIII concentrate and that included at 
least 25 patients with follow-up were included in the 
analysis. Thirty-three independent cohorts of PTPs with 
4,323 subjects and 43 incident de novo inhibitors were 
found and analysed. This systematic review confirmed 
a low overall rate of de novo inhibitors in PTPs, 
without any significant effect of putative predictors, 
including the type of FVIII concentrate. Nevertheless, 
the proper methodology to address the issue of the 
comparative immunogenicity of different products 
and/or associations with switching must be identified. 
Requisites are to assess the baseline risk, to take into 
account the attributable risk fraction and to have control 
groups with the least confounders possible. These 
conditions can be met in a retrospective fashion, with 
large, rigorous nested-case control studies embedded 
in prospective registries, or with large prospective 
controlled observations. The National Institutes of 
Health inhibitor study is an example of the former. The 
EUHASS project is an example of the latter. EUHASS 
is a pharmacovigilance programme to monitor the 
safety of treatments for people with inherited bleeding 
disorders in Europe. Haemophilia treatment centres 
report adverse events directly to the EUHASS website 
and regular surveillance reports are produced. It is 
also recommended that all haemophilia centres and 
countries planning to switch patients to new FVIII 
concentrates enrol both switching and non-switching 
patients in registries, test for inhibitors immediately 
before the switch and at a minimum of at least 1-2 
months after the switch, and formally report their data, 
either individually or in collaboration.
Clinical significance of low- and high-titre 
inhibitors
Inhibitors are classified into low or high-responding 
inhibitors based on a patient's peak inhibitor titre 
after repeated FVIII exposure. The International 
Society on Thrombosis and Haemostasis Scientific 
and Standardisation Committee has recommended 
that an inhibitor titre of 5 BU differentiates low- from 
high-responding inhibitors. An antibody titre that is 
persistently below 5 BU despite repeat challenges 
with FVIII is considered a low-responding inhibitor. 
An inhibitor is considered to be high-responding if the 
assay values have been greater than 5 BU at any time. 
Elena Santagostino reported the cumulative incidence 
of low-response and high-response inhibitors, adjusted 
for genetic and non-genetic risk factors, over a 20-year 
period in the cohort of PUPs with severe haemophilia 
A from the CANAL study (1990-2000) and PedNet 
Registry (2000-2009). Patients were consecutively 
recruited from 31 haemophilia treatment centres in 
16 countries and followed until 50 ED or inhibitor 
development. Inhibitor development was studied in 
5-year birth cohorts comparing cumulative incidences. 
Furthermore, the risk of inhibitor development per 
5-year birth cohort was studied using multivariable Cox 
regression analysis, adjusting for potential genetic and 
treatment-related confounders. Overall, 926 PUPs were 
included with a total cumulative inhibitor incidence of 
27.5%. The inhibitor incidence increased from 19.5% 
in 1990-1994 to 30.9% in 2000-2004. The incidence of 
low-titre inhibitors increased from 3.1% in 1990-1994 
to 10.5% in 2005-2009, while the incidence of high-titre 
inhibitors remained stable over time. In conclusion, the 
cumulative incidence of inhibitors in PUPs increased 
significantly between 1990 and 2009, but the incidence 
of high-titre inhibitors remained stable. The increased 
inhibitor incidence in severe haemophilia A since 1990 is 
attributable to the detection of more low-titre inhibitors.
Genetics of inhibitors 
How next-generation sequencing can help to 
understand inhibitor risk better
The risk of developing inhibitors is highest during 
the first 20 ED. If the patient can be brought through 
this high-risk period without inhibitor development, the 
subsequent risk is low. Johannes Oldenburg reported 
that risk factors for inhibitor development could be 
divided into genetic factors (patient-related) and 
environmental factors (non-patient-related). Genetic 
risks include ethnicity, family history, severity of 
haemophilia, severity of F8 gene anomalies (i.e., F8 
gene mutations, intron 22 inversion mutation) and 
immune response genes (i.e., polymorphisms), while 
environmental factors include treatment regimen, type of 
concentrate and danger signals. Literature data indicated 
that minimising danger signals during the first 20 ED 
may reduce the risk of the formation of inhibitors to 
FVIII. These results should be confirmed in a large, 
prospective clinical study. In addition, currently only 
a few parameters can be built into risk models. Next-
generation sequencing may facilitate more complete data 
assessments and, thus, help to construct more complex 
risk assessment models. 
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Treatment of inhibitors
The development of alloantibodies that neutralise 
FVIII activity renders patients with haemophilia A 
resistant to FVIII replacement therapy and increases 
the risk of unmanageable bleeding and of associated 
morbidity, such as severe arthropathy and disability. 
Bleeding episodes and surgical interventions in 
patients with FVIII inhibitors are difficult to control, 
requiring bypassing agents; the current choices include 
activated prothrombin complex concentrates (aPCC) or 
recombinant activated FVII (rFVIIa). 
Experience on bypassing therapy in patients with 
inhibitors. Successes and failures: what else is 
necessary?
M. Elisa Mancuso reported that both aPCC and 
rFVIIa have been successfully used to cover major 
and minor orthopaedic and non-orthopaedic surgical 
procedures in patients with inhibitors. Moreover, 
these products have been used to prevent bleeding 
episodes and reduce bleeding frequency with good 
results, although not comparable to those of standard 
prophylaxis in patients without inhibitors. It was 
demonstrated that aPCC and rFVIIa are equally 
effective for the treatment of acute bleeds. 
It has not so far been demonstrated that there is a 
significant difference in bleeding frequency between 
patients with or without inhibitors, but the management 
of bleeding episodes in the presence of high-titre 
inhibitors is more problematic. Finally, the risk of 
thrombotic adverse events is similar and quite low in 
congenital haemophilia A. The use of these products 
needs to be optimised and larger cohorts should be 
studied in order to understand the different haemostatic 
responses. 
The role of non-replacement products (antithrombin, 
anti-tissue factor pathway inhibitor, bi-specific 
antibodies)
David Lillicrap underlined that it is important to 
consider the existence of other strategies to induce 
haemostasis in patients with FVIII inhibitors: FVIII 
mimetic therapy (ACE910) and rebalancing haemostasis 
by anti-thrombin inhibition (fitusiran) and inhibition of 
tissue factor pathway inhibitor (concizumab). Phase 
I data indicate that antibody therapy with ACE910 is 
well tolerated and has a promising efficacy profile in 
patients with severe haemophilia A. Early data suggest 
an encouraging reduction in bleeding rates in all patients. 
ACE910 shows promise as a preventive treatment for 
haemophilia A, irrespectively of the presence of FVIII 
inhibitors. Interim results, presented at the American 
Society of Hematology (ASH) 2015 Annual Meeting, 
showed that monthly subcutaneous administration 
of fitusiran achieved potent and dose-dependent 
lowering of anti-thrombin of up to 88% in patients 
with haemophilia. This lowering of anti-thrombin was 
associated with statistically significant increases in 
thrombin generation and an 85% reduction in estimated 
median annualised bleeding rates in all evaluable 
cohorts. The observed bleeding rates were comparable 
to those reported for prophylactic intravenous infusions 
of replacement factors in patients with haemophilia. 
To date, fitusiran has been found to be generally well 
tolerated: furthermore, there have been no reports 
of thromboembolic events or clinically significant 
increases in D-dimer, a biomarker of excessive clot 
formation. Concizumab showed a favourable safety 
profile after intravenous or subcutaneous administration 
of a single dose and non-linear pharmacokinetics 
were observed due to target-mediated clearance. 
A concentration-dependent procoagulant effect of 
concizumab was noted, supporting further study into 
the potential use of subcutaneous concizumab for the 
treatment of haemophilia.
Eradication of inhibitors by immune tolerance 
induction 
International data
Charles R.M. Hay spoke about immune tolerance 
induction (ITI) i.e., the only proven strategy for FVIII 
inhibitor eradication. No standard ITI regime exists; 
protocols include the Bonn protocol (high-dose FVIII 
twice daily), the Malmo protocol and the low-dose 
van-Creveld protocol. Proposed predictors of success 
are the following:
- inhibitor titre: historical peak <200 BU, starting titre 
<10 BU and peak on ITI;
- anti-A2, anti-A1, anti-HC(RAR);
- low-risk F8 genotype;
- age at start of ITI;
- interval of ≤5 years from inhibitor diagnosis to ITI;
- stopping treatment early or taking breaks in the 
treatment schedule (missed doses) may interfere with 
the success of ITI and/or increase the time it takes 
for the person with inhibitors to achieve tolerance.
Researchers are evaluating whether the type or brand 
of factor concentrate (intermediate- or high-purity 
plasma-derived factor concentrates or recombinant 
products) used in ITI can influence the success of 
therapy. So far, similar success rates have been obtained 
with both recombinant and plasma-derived products. 
With ITI therapy, factor concentrate is given regularly 
over a period until the immune system is trained to 
recognise the treatment product without reacting to 
it. When ITI is successful, inhibitors disappear and 
the patient's response to factor concentrates returns to 
normal. The majority of people who undergo ITI will 
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see an improvement within 12 months, but more difficult 
cases can require 2 years or longer.
In this context, Charles R.M. Hay also presented 
the results of the ongoing Observational ITI (ObsITI) 
study that is evaluating ITI in haemophilia A patients 
with inhibitors and potential predictors of ITI outcome 
and morbidity; in particular, the influence of VWF in 
FVIII concentrates. Clinical experience in Germany 
suggested that ITI may be more successful with FVIII/
VWF concentrates using the Bonn protocol (87-91%) 
compared with some subsequently introduced rFVIII 
concentrates lacking VWF (success rates 29-54%). Later 
return to the use of FVIII/VWF concentrates again saw 
greater success rates of around 80%. ObsITI provides 
a rare opportunity to prospectively evaluate diverse 
FVIII products under consistent study conditions. 
Moreover, ObsITI includes inhibitor patients with 
poor prognostic risk factors and applies particularly 
stringent ITI success criteria. Prospective interim 
ObsITI data were presented for those ITI patients who 
received a single pdFVIII/VWF concentrate, mainly 
according to the Bonn protocol. These data are for the 
largest poor-prognosis group to date to prospectively 
undergo ITI with a single pdFVIII/VWF concentrate, 
thus avoiding confounding factors related to product 
differences. The main objectives were to examine ITI 
outcomes and the association of prognostic factors with 
these outcomes. In the interim analysis of the ObsITI 
study, over 80% of patients had at least one risk factor 
for poor ITI prognosis at the start of the tolerance 
induction. Nonetheless, 70.8% achieved complete 
success, with no relapses, despite exceptionally stringent 
success criteria. Moreover, 62.9% of patients with ≥1 
poor prognostic factor achieved complete success. ITI 
outcome was significantly associated with inhibitor titre 
at the start of ITI, number of poor prognostic factors, 
monthly bleeding rate during ITI and peak inhibitor 
titre during ITI. In conclusion, treatment with a single 
pdFVIII/VWF concentrate, mainly according to the 
Bonn protocol, resulted in a high rate of ITI success 
in haemophilia A patients with inhibitors and poor 
prognosis for ITI success. The ongoing ObsITI study 
will continue to provide valuable prospective reports on 
ITI in haemophilia A patients with inhibitors.
The Italian experience of immune tolerance induction
Considering the importance of genetic factors, 
Giovanni Di Minno discussed data concerning the 
relationship between F8 genotype and ITI outcome in 
patients with severe haemophilia A and high-responding 
inhibitors. To investigate this relationship, F8 mutations 
were identified in 86 patients recruited as part of the 
Italian ITI registry (the PROFIT study). ITI outcome 
was centrally reviewed according to the following 
definitions: success (undetectable inhibitor and normal 
FVIII pharmacokinetics); partial success (inhibitor titre 
<5 BU/mL and/or abnormal FVIII pharmacokinetics); 
and failure. F8 mutations known to be associated with 
a high risk of inhibitor development (large deletions, 
inversions, nonsense mutations and splice site mutations) 
were found in 70 patients (81%); among these, the intron 
22 inversion was present in 49 patients (57%). In 16 
patients (19%) lower-risk F8 defects (small insertions/
deletions and missense mutations) were identified. The 
latter group of patients showed a significantly higher ITI 
success rate than those carrying high-risk mutations. On 
multivariable analysis, the mutation risk class remained 
a significant predictor of success; other significant 
predictors were inhibitor titre at the start of ITI and 
peak titre during ITI. In conclusion, the success of ITI 
is influenced by F8 genotype. This knowledge should 
contribute to the stratification of prognosis and to the 
clinical choices made regarding ITI for patients with 
high-responding inhibitors.
Inhibitors in mild haemophilia
The INSIGHT study
The association between F8 mutation and inhibitor 
development was also observed in patients with non-
severe haemophilia A (FVIII 2-40 IU/dL). In this 
regard, Alice S. van Velzen presented the INSIGHT 
study. This analysis included 1,112 patients with non-
severe haemophilia A from 14 centres in Europe and 
Australia that had genotyped at least 70% of their 
patients. Inhibitor risk was calculated as a Kaplan-Meier 
incidence with cumulative number of ED as the time 
variable. During 44,800 ED (median, 24 ED per patient; 
interquartile range [IQR], 7-90), 59 of the 1,112 patients 
developed an inhibitor, with a cumulative incidence 
of 5.3% after a median of 28 ED. The inhibitor risk 
at 50 ED was 6.7% and at 100 ED the risk had further 
increased to 13.3%. Among a total of 214 different F8 
missense mutations 19 were associated with inhibitor 
development. These results highlight the importance of 
F8 genotyping in non-severe haemophilia A.
Optimal diagnosis and treatment of patients 
with acquired haemophilia
This Conference also considered acquired 
haemophilia A which is an autoimmune disease caused 
by an inhibitory autoantibody to FVIII. The approximate 
incidence of this condition is 1.48 cases/million per year. 
The therapeutic aim is two-fold: control of bleeding (of 
variable intensity at presentation) and eradication of the 
antibody by immunosuppressive treatment.
Craig Kessler reported that bleeds may be severe 
and potentially life-threatening in >70% of cases: in the 
EACH2 Registry 70.3% of the bleeding episodes that 
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occurred were rated as severe. Most deaths within the 
first week are due to gastrointestinal and lung bleeding, 
later deaths result from intracranial and retroperitoneal 
haemorrhages. Fatal bleeding can occur up to 5 months 
after the first presentation if the autoantibodies are 
not eliminated. Diagnostic delays have a significant 
impact on the interval between onset of bleeding and 
the start of haemostatic therapy. First-line treatment 
options for bleeding episodes are rFVIIa and aPCC. 
Prophylactic use of bypassing agents prior to minor 
or major invasive procedures is recommended. Acute 
reduction or removal of the inhibitor to facilitate 
haemostasis using plasmapheresis or immunoadsorption 
may be applied under special circumstances. First-
line immunosuppressive treatment is represented by 
corticosteroids ± cyclophosphamide.
Eradication of autoantibodies
In this regard, Peter Knöbl reported the results of a 
German, Austrian, and Swiss registry (GTH-AH study) 
of acquired haemophilia in order to identify prognostic 
factors that may guide the choice of immunosuppressive 
treatment to eradicate the autoantibody contributing 
to the outcome of the syndrome. Immunosuppressive 
treatment is associated with frequent adverse events, 
including infections as a leading cause of death. 
Predictors of time to remission could help to guide the 
intensity of immunosuppressive treatment but have 
not been established. Prognostic factors were analysed 
in 102 prospectively enrolled patients treated with a 
uniform immunosuppressive treatment protocol. Partial 
remission (defined as no active bleeding, FVIII restored 
to >50 IU/dL, haemostatic treatment stopped for >24 
hours) was achieved by 83% of patients after a median 
of 31 days. Patients with a baseline FVIII <1 IU/dL 
achieved partial remission less often and later (77%, 
43 days) than patients with a baseline level ≥1 IU/dL 
(89%, 24 days). After adjustment for other baseline 
characteristics, low FVIII levels remained associated 
with a lower rate of partial remission. In contrast, the 
achievement of partial remission in ≤21 days on steroids 
alone was more common in patients with FVIII ≥1 IU/dL 
and inhibitor concentration <20 BU/mL. Low FVIII was 
also associated with a lower rate of complete remission 
and decreased survival. Thirty percent of the adverse 
events occurred in relation to the immunosuppressive 
treatment, including infections, which were the 
leading cause of death. A high rate of infections and 
related mortality has been confirmed in the available 
studies (11%, 4%, and 12% of patients in a United 
Kingdom surveillance study and in the EACH2 and 
SACHA registries, respectively), whereas death due to 
bleeding, compared with historical data, has decreased 
substantially in the last few years (from 22% to 2.9%).
In conclusion, presenting FVIII levels and inhibitor 
titre are potentially useful to tailor immunosuppressive 
treatment in acquired haemophilia A. Hence, this 
study established clinically useful prognostic factors 
for remission and survival of patients with acquired 
haemophilia A. However, it also confirmed that current 
immunosuppressive treatment regimens often require 
a very long time to achieve remission and that side 
effects still cause considerable morbidity and mortality. 
The challenge for future studies will be to develop 
immunosuppressive treatment regimens that reduce 
the burden of side effects, potentially by tailoring 
their intensity to prognostic baseline characteristics 
established in the current study.
Cost of inhibitor treatment. 
A pharmaco-economic perspective
During this meeting, the cost of inhibitor treatment 
was also considered. Lorenzo G. Mantovani focussed 
on the fact that inhibitors in patients with haemophilia 
are a complication causing pain and disability, thus 
impairing quality of life. The Cost of Care - Inhibitors 
Study (COCIS) group and the Immune Tolerance 
Economics Retrospective (ITER) study showed that 
haemophilia complicated by inhibitors required very 
substantial resources for management in order to provide 
a satisfactory quality of life. The aim of medical science 
is to improve the capacity to treat the most severe 
manifestations of the disease effectively. The expectation 
is that society will reward this pursuit of new medical 
knowledge by providing the resources enabling it to be 
translated into better care for patients. 
Patients' needs were identified: improve medical 
understanding (risk factors and clinical management); 
facilitate access to diagnosis and treatment; inform and 
educate.
Finally, specific standards are needed on tailored 
comprehensive care and all stakeholders must be 
engaged.
Patients' views and expectations: 
WFH and EHC initiatives
Mark Brooker from the World Federation of 
Hemophilia (WFH) stated that, with the exception of 
lack of access to treatment, inhibitor development is 
the most significant challenge in haemophilia care. 
The needs of patients with inhibitors include improved 
medical understanding which translates into possible 
prevention and better management for patients. This 
also means determining good clinical management, for 
example, how best to treat patients with inhibitors, how 
to provide prophylaxis for patients with haemophilia 
with inhibitors, how to ensure haemostasis during 
surgery, how best to manage acute bleeds and what 
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new products can do this, etc. The WFH's efforts to 
address the needs of patients with inhibitors include 
the promotion and expansion of research, focussing on 
patients' risk in addition to product risk. The WFH also 
promotes data collection and international collaboration, 
encouraging each patient to be in a registry; harmonises 
definitions; and ensures that there is a way to monitor 
large groups of patients over the long term. To improve 
diagnosis and access to treatment products, the WFH 
runs laboratory training workshops and has produced 
an online video demonstration of inhibitor assays 
(coming later this year). Inhibitor testing has been added 
to International External Quality Assessment Scheme 
(IEQAS) for monitoring the capacity of centres to make 
accurate diagnoses. The WFH produces educational 
resources for patients, families and healthcare providers, 
including patient booklets, resources for physicians, 
panel discussions, online demonstration videos on 
laboratory testing and a dedicated eLearning centre on 
a new platform, to be launched in July.
In Europe, given the small numbers of people with 
haemophilia who have inhibitors in each nation, these 
patients, their families and caregivers are an underserved 
and isolated subgroup within the European haemophilia 
population and face significant personal and systemic 
challenges, including insufficient treatment, lack 
of information, etc. Amanda Bok presented results 
from two surveys that the European Haemophilia 
Consortium (EHC) conducted among national member 
organisations and individual patients/family members/
caregivers, respectively, and outlined the main elements 
of the European Inhibitor Network (EIN) programme, 
which was built based on the surveys' findings. The 
EIN is a new multi-faceted, multi-annual programme 
of the EHC seeking to: improve understanding of this 
subpopulation's specific needs and how to meet them; 
build a community of inhibitor patients, families and 
caregivers to promote mutual support, education and 
empowerment; provide education and advocacy training 
to support direct engagement with decision-makers; and 
work with medical experts towards an agreed framework 
of treatment and care. 
How EMA and FDA are tackling the problem 
of inhibitor development
International authorities (the European Medicines 
Agency [EMA] and the American Food and Drug 
Administration [FDA] represented by Anneliese Hilger 
and Zuben E. Sauna, respectively) give guidance 
when an application for a marketing authorisation for 
recombinant or human plasma-derived FVIII products 
is made for use in treatment and prevention of bleeding 
in patients with haemophilia A. The guidance covers 
clinical investigations to be conducted before and after 
marketing authorisation. Guidance is also provided for 
authorised products when a significant change in the 
manufacturing process has been made.
Efficacy must be demonstrated in clinical trials, which 
need to be conducted before marketing authorisation 
is requested and combined with the commitment to 
perform post-authorisation investigation(s) to collect 
additional clinical data and to create a bridge in the long-
term between outcomes in clinical trials and outcomes 
following routine use. When clinically evaluating human 
plasma-derived or recombinant coagulation factors for 
the treatment of haemophilia A, the initial trial typically 
examines the pharmacokinetics of the main active factor. 
Furthermore, the clinical efficacy of FVIII treatment 
(e.g. prophylaxis, on demand) should be assessed 
during a period of a minimum of 50 ED by the patients 
themselves and the treating physicians.
Safety aspects of FVIII products include viral 
safety, immunogenicity and other adverse events. The 
occurrence of neutralising antibodies to FVIII, which 
is a major complication in haemophilia A treatment, 
is considered to be a serious adverse event and should 
be recorded and reported; this requirement should be 
included in all study protocols.
In general, immunogenicity should be investigated 
prior to requesting marketing authorisation and 
substantiated with post-marketing studies. The risk of 
inhibitor occurrence is higher in patients with severe 
haemophilia A than in patients with moderate and 
mild disease; the genotype (high risk: inversions, large 
deletions or nonsense mutations of the F8 gene) and 
ethnic background of the patient are also relevant. 
In addition, risk may be associated with treatment 
initiation in PUPs, with switching treatment or with 
alterations to the antigenicity of a product due to 
changes in manufacturing processes. PTPs are the most 
suitable candidates in whom to test the product-related 
immunogenicity of a FVIII product. The diagnosis of a 
FVIII inhibitor will be based on clinical observations and 
be confirmed by FVIII inhibitor testing in the laboratory.
Neutralising antibodies are the most important 
immunological concern and, therefore, the following 
aspects and basic principles should be considered:
- inhibitor development should be evaluated in PTPs 
(>150 ED, suffering from severe haemophilia A with 
a FVIII level <1%);
- the modified Nijmegen method of the Bethesda 
assay should be used. Validated testing should be 
performed in a central laboratory;
- in the case of positive results for an inhibitor, inhibitor 
retesting using a second separately drawn sample should 
be performed in a central laboratory for confirmation. 
The sampling time-points should be recorded and 
included in the serious adverse events report;
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- the defined thresholds are ≥0.6 BU for "a low-titre" 
inhibitor and >5 BU for a "high-titre" inhibitor;
- preferably, inhibitor testing should be performed 
when the FVIII level has reached baseline;
- patients' characteristics should be recorded in detail: 
ethnicity, family history, lifestyle, general health 
status, infection status, type of F8 gene mutation, 
reason for treatment, date of treatment initiation, kind 
of treatment (on demand, prophylactic, continuous 
infusion).
Since children may respond differently compared to 
adults, so a multicentre trial should include at least 50 
children allocated to two age cohorts. A minimum of 
25 patients should be PTPs aged 6-12 years and at least 
25 patients should be <6 years who have undergone 
>50 ED with previous FVIII products. The clinical trial 
in children <12 years should not started before safety 
has been proven for 50 ED each in 20 patients, who are 
included in the PTP trial of patients ≥12 years. The post-
marketing investigation can include PTPs (>150 ED) of 
any age, provided that a balanced age distribution can 
be achieved (approximately 60 patients <12 years out 
of 200 patients). Furthermore, patients <12 years can 
only be enrolled in the post-marketing investigation 
when the pre-authorisation study in children <12 years 
has been completed. 
The approval of the indication in PUPs will be based 
on a clinical trial in a minimum of 50 PUPs evaluated 
for efficacy and safety during at least 50 ED connected 
with a post-approval commitment to follow up at least 
100 PUPs (50 from the efficacy/safety trial and 50 new 
patients) for a minimum of 100 ED. The clinical trial in 
PUPs should commence when data are available from the 
20 patients participating in the trial of children <12 years 
with 50 ED each, including a minimum of 10 patients 
<6 years, and when pharmacokinetic investigations 
in children have been performed. A PUP study needs 
to be conducted for all novel rFVIII products, such as 
novel genetic constructs or modifications of the FVIII 
molecule in order to alter its in vivo properties (e.g. 
pharmacokinetics) and for FVIII products manufactured 
with novel production methods (e.g. a new cell line with 
which there is limited experience). In the case of pdFVIII 
products (e.g. manufactured with novel methods), the 
need for PUP studies will be considered on a case-by-
case basis.
All these considerations underline the importance 
that each PUP should be included in a registry, at least 
a national one. Moreover, there is a strong need to 
define a minimum common and relevant dataset and/or 
to organise the conditions of interoperability between 
registries in order to collect information on inhibitor 
incidence in this population rapidly at the international 
level. This is an urgent task as several innovative 
concentrates will soon be introduced on the market for 
which there is limited information available on their 
long-term immunogenic risk. On the other hand, in this 
regard, it is important to underline that no randomised 
clinical trials (except for SIPPET) are available to 
provide the evidence that is needed: it is not possible 
to reach definitive conclusions on the incidence of 
inhibitors with each of the FVIII products, because of 
differences in the study designs of safety trials. Since 
it is not known whether new recombinant products are 
more immunogenic than plasma-derived ones, there is 
a need for randomised clinical trials to provide definite 
answers to the questions concerning the immunogenicity 
of FVIII products.
Disclaimer
This summary is not a full and complete recitation of 
the conference. It is an attempt to capture, in broad 
terms, the nature and the scope of the comments. The 
summary has been prepared in an effort to highlight key 
elements of the presentations in a concise format, not 
to replace them. Every effort has been made to avoid 
mischaracterisation and to present the views provided 
fairly. Any failure to do so is unintentional.
Images are publicly available from the Speakers' 
presentations published at the Conference website www.
smc-media.eu/inhibitors/ and sourced to the original 
source when available.
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